Biocon Biologics gains FDA approval for Yesafili, shares up

Biocon Biologics Ltd, a subsidiary of Biocon Ltd, secured U.S. FDA approval for Yesafili, an interchangeable biosimilar to Eylea (aflibercept). Yesafili is designed to treat ophthalmological conditions, including neovascular age-related macular degeneration, visual impairment due to macular edema secondary to retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization.

Biocon Biologics Ltd, a subsidiary of Biocon Ltd, secured U.S. FDA approval for Yesafili, an interchangeable biosimilar to Eylea (aflibercept). Yesafili is designed to treat ophthalmological conditions, including neovascular age-related macular degeneration, visual impairment due to macular edema secondary to retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization.   

The company reported, the approval follows previous authorisations in Europe and the United Kingdom in 2023, where Yesafili was the first biosimilar aflibercept to be approved. The company set a launch date for Yesafili in Canada by July 1, 2025, as stipulated by a settlement agreement. 

Also Read: Biocon to invest ₹2,200 crore in capex in the next 2 yearsShreehas Tambe, CEO & Managing Director of Biocon Biologics Ltd.,said, ““The FDA approval of YESAFILI (aflibercept) as the first interchangeable biological product to Eylea is a significant milestone for Biocon Biologics marking our entry into Ophthalmology, a new therapeutic area in the United States. YESAFILI is approved for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy. This approval builds on our successful track record of bringing the first interchangeable insulin, SEMGLEE, the first biosimilar Trastuzumab, OGIVRI, and the first biosimilar Pegfilgrastim, FULPHILA, to patients in the United States.” 

The shares were up by 1.33% to ₹308.75 at 10.40 am on the BSE.  

Like (0)
Previous May 21, 2024 3:59 pm
Next May 21, 2024 3:59 pm

Related posts

  • TBO Tek IPO: Listing today; strong gains expected

    Shares of TBO Tek will be listed on the bourses today. The company has fixed the price at ₹920, the upper end of the price band ₹875-920.

    US stock market May 15, 2024
  • F&O Strategy: GAIL (India): Bull call spread

    The stock of GAIL (India) (₹221.83) finds an immediate support at ₹209. A major support is at ₹166. The short and long-term outlook appears bright. If the current trend sustains, the stock has the potential to reach ₹261 and for that it should not break ₹194. We expect the momentum to continue for GAIL (India).

    US stock market 1 day ago
  • The top ten largest holdings of public funds are exposed! Zhang Kun’s performance was “given a thumbs up” by CNOOC

    Source: Market Value Storm It’s rare to guess right once. Author | Market Value Fengyun Fund Research Department Editor | Xiaobai April every year is the intensive disclosure period for the first quarter reports of public funds. As of April 24, most funds in the market have disclosed their first quarter reports for 2024. Choice data shows that the size of the public fund market reached a new high in the first quarter, reaching 28.8 trillion yuan, a month-on-month increase of 5.6%. The scale of ETFs also continued to exceed the highest point, with the current scale reaching 2.4 trillion yuan, and the scale of non-monetary ETFs exceeded 2 trillion yuan. . The disclosure of the first quarter report can not only give us a macro feeling of the entire fund market, but we can also understand which stocks public funds prefer, what changes are in public positions, and the specific allocation of various industries through the content of the first quarter report. To this end, Fengyun Junte compiled the list of the top ten largest holdings of public funds…

    US stock market April 25, 2024
  • BSE to take steps to mitigate options volatility

    The BSE is taking steps to mitigate sudden spikes in options prices. The bourse had seen sudden spurts in two of its derivatives indices on February 2 and April 12, which has prompted the exchange to ramp up surveillance measures. It recently introduced what is called a “limit price protection”, which will place restrictions on the price range for orders in the derivatives market.

    US stock market May 13, 2024
  • China Resources Micro (688396.SH): Net profit in 2023 will decrease by 43.48% year-on-year

    Gelonghui April 25 | China Resources Micro (688396.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 9.901 billion yuan, a year-on-year decrease of 1.59%; net profit attributable to shareholders of listed companies was 1.479 billion yuan, a year-on-year decrease of 1.479 billion yuan. A decrease of 43.48%; net profit attributable to shareholders of listed companies after excluding non-recurring gains and losses was 1.127 billion yuan, a year-on-year decrease of 49.97%; basic earnings per share was 1.1206 yuan per share. The company plans to distribute a cash dividend of 1.118 yuan (tax included) to all shareholders for every 10 shares.

    US stock market April 25, 2024
  • Jingneng Clean Energy (00579): Chen Dayu was appointed chairman of the board of directors

    Following Zhang Fengyang\’s resignation, executive director Chen Dayu was appointed as the chairman of the board of directors, with a term starting from April 25, 2024 until the expiration of the fifth term of the board of directors, and was appointed as the authorized representative, effective from April 25, 2024.

    US stock market April 25, 2024